Cargando…

Treatment and survival analysis for 40-year SEER data on upper esophageal cancer

BACKGROUND: Upper esophageal cancer (UEC) is rare in both Eastern and Western countries. The epidemiological characteristics and long-term survival of UEC patients are less known. In addition, the choice of optimal treatment for UEC has been controversial. METHODS: Cases of UEC (C15.3 and C15.0) ari...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xi, Zhu, Ming-Chuang, Li, Guo-Liang, Xiong, Peng, Sun, Wei, Zhang, Ni, Zhao, Bo, Li, Le-Qun, Fu, Xiang-Ning, Zhu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387539/
https://www.ncbi.nlm.nih.gov/pubmed/37529246
http://dx.doi.org/10.3389/fmed.2023.1128766
_version_ 1785081903325380608
author Wu, Xi
Zhu, Ming-Chuang
Li, Guo-Liang
Xiong, Peng
Sun, Wei
Zhang, Ni
Zhao, Bo
Li, Le-Qun
Fu, Xiang-Ning
Zhu, Min
author_facet Wu, Xi
Zhu, Ming-Chuang
Li, Guo-Liang
Xiong, Peng
Sun, Wei
Zhang, Ni
Zhao, Bo
Li, Le-Qun
Fu, Xiang-Ning
Zhu, Min
author_sort Wu, Xi
collection PubMed
description BACKGROUND: Upper esophageal cancer (UEC) is rare in both Eastern and Western countries. The epidemiological characteristics and long-term survival of UEC patients are less known. In addition, the choice of optimal treatment for UEC has been controversial. METHODS: Cases of UEC (C15.3 and C15.0) arising during the period from 1973 to 2013 were identified and selected using the SEER database. Student's t-test and Pearson's chi-square test were used to compare the differences in parameters among different groups. Esophageal cancer-specific survival (ECSS) and overall survival (OS) rates were calculated by using the Kaplan–Meier method. Cox proportional hazard regression was used to analyze predictive factors. RESULTS: In the past 40 years, the cases of UEC have gradually increased, and the proportion of adenocarcinoma (AD) has gradually increased (from 3.6% to 11.8%, p < 0.001). There has been a significant increase (1973–1982 vs. 2004–2013) in median OS (7 months vs. 10 months, p < 0.001) and median ECSS (7 months vs. 11 months, p < 0.001) among UEC patients from 1973 to 2013. For the impact of different treatments, the results showed that the ECSS and OS of surgery without radiation (SWR) and radiation plus surgery (R+S) were superior to those of radiation without surgery (RWS). Subgroup analysis showed that ECSS and OS were highest among patients treated with SWR compared with R+S and RWS for patients with localized disease. For regional disease, ECSS and OS were highest among patients with R+S compared with SWR or RWS. Among patients with regional-stage squamous cell carcinoma (SCC), OS was higher with neoadjuvant radiotherapy or adjuvant radiotherapy compared with SWR. Multivariate analysis showed that radiotherapy sequence was dependently associated with OS among patients with regional-stage SCC. CONCLUSION: Although the long-term survival of UEC remains poor, it has gradually increased since 1973. This should be closely related to the improvement of medical care over the past 40 years. Different treatment methods have a great influence on the long-term survival of UEC. For localized diseases, surgery may be a better choice. For regional disease, surgery plus adjuvant or neoadjuvant radiotherapy may be more beneficial to improve the long-term prognosis of UEC patients.
format Online
Article
Text
id pubmed-10387539
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103875392023-08-01 Treatment and survival analysis for 40-year SEER data on upper esophageal cancer Wu, Xi Zhu, Ming-Chuang Li, Guo-Liang Xiong, Peng Sun, Wei Zhang, Ni Zhao, Bo Li, Le-Qun Fu, Xiang-Ning Zhu, Min Front Med (Lausanne) Medicine BACKGROUND: Upper esophageal cancer (UEC) is rare in both Eastern and Western countries. The epidemiological characteristics and long-term survival of UEC patients are less known. In addition, the choice of optimal treatment for UEC has been controversial. METHODS: Cases of UEC (C15.3 and C15.0) arising during the period from 1973 to 2013 were identified and selected using the SEER database. Student's t-test and Pearson's chi-square test were used to compare the differences in parameters among different groups. Esophageal cancer-specific survival (ECSS) and overall survival (OS) rates were calculated by using the Kaplan–Meier method. Cox proportional hazard regression was used to analyze predictive factors. RESULTS: In the past 40 years, the cases of UEC have gradually increased, and the proportion of adenocarcinoma (AD) has gradually increased (from 3.6% to 11.8%, p < 0.001). There has been a significant increase (1973–1982 vs. 2004–2013) in median OS (7 months vs. 10 months, p < 0.001) and median ECSS (7 months vs. 11 months, p < 0.001) among UEC patients from 1973 to 2013. For the impact of different treatments, the results showed that the ECSS and OS of surgery without radiation (SWR) and radiation plus surgery (R+S) were superior to those of radiation without surgery (RWS). Subgroup analysis showed that ECSS and OS were highest among patients treated with SWR compared with R+S and RWS for patients with localized disease. For regional disease, ECSS and OS were highest among patients with R+S compared with SWR or RWS. Among patients with regional-stage squamous cell carcinoma (SCC), OS was higher with neoadjuvant radiotherapy or adjuvant radiotherapy compared with SWR. Multivariate analysis showed that radiotherapy sequence was dependently associated with OS among patients with regional-stage SCC. CONCLUSION: Although the long-term survival of UEC remains poor, it has gradually increased since 1973. This should be closely related to the improvement of medical care over the past 40 years. Different treatment methods have a great influence on the long-term survival of UEC. For localized diseases, surgery may be a better choice. For regional disease, surgery plus adjuvant or neoadjuvant radiotherapy may be more beneficial to improve the long-term prognosis of UEC patients. Frontiers Media S.A. 2023-07-17 /pmc/articles/PMC10387539/ /pubmed/37529246 http://dx.doi.org/10.3389/fmed.2023.1128766 Text en Copyright © 2023 Wu, Zhu, Li, Xiong, Sun, Zhang, Zhao, Li, Fu and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wu, Xi
Zhu, Ming-Chuang
Li, Guo-Liang
Xiong, Peng
Sun, Wei
Zhang, Ni
Zhao, Bo
Li, Le-Qun
Fu, Xiang-Ning
Zhu, Min
Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
title Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
title_full Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
title_fullStr Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
title_full_unstemmed Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
title_short Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
title_sort treatment and survival analysis for 40-year seer data on upper esophageal cancer
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387539/
https://www.ncbi.nlm.nih.gov/pubmed/37529246
http://dx.doi.org/10.3389/fmed.2023.1128766
work_keys_str_mv AT wuxi treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT zhumingchuang treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT liguoliang treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT xiongpeng treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT sunwei treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT zhangni treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT zhaobo treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT lilequn treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT fuxiangning treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer
AT zhumin treatmentandsurvivalanalysisfor40yearseerdataonupperesophagealcancer